Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
62
-
Total 13F shares, excl. options
-
51,839,170
-
Shares change
-
-139,230
-
Total reported value, excl. options
-
$29,049,633
-
Value change
-
-$98,488
-
Put/Call ratio
-
38%
-
Number of buys
-
22
-
Number of sells
-
-29
-
Price
-
$0.5604
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q1 2023
84 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q1 2023.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 62 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51,839,170 shares
of 236,234,693 outstanding shares and own 22% of the company stock.
Largest 10 shareholders include Alerce Investment Management, L.P. (16,205,119 shares), VANGUARD GROUP INC (12,510,904 shares), ACADIAN ASSET MANAGEMENT LLC (7,483,053 shares), BlackRock Inc. (2,703,522 shares), RENAISSANCE TECHNOLOGIES LLC (2,338,500 shares), GEODE CAPITAL MANAGEMENT, LLC (1,682,498 shares), JACOBS LEVY EQUITY MANAGEMENT, INC (1,198,724 shares), FEDERATED HERMES, INC. (1,020,032 shares), MILLENNIUM MANAGEMENT LLC (910,958 shares), and STATE STREET CORP (692,836 shares).
This table shows the top 62 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.